Renal & Urology News
Caroline Helwick
February 05, 2010
NEW ORLEANS—Acute renal failure (ARF) induced by pathogenic light chains can be the first presenting sign of multiple myeloma, and prompt treatment of the malignancy is critical to reversing renal damage, according to a study presented by European investigators at the American Society of Hematology 51st annual meeting.
“This is an oncologic emergency and you need very active myeloma treatment to correct...
ScienceDaily (Jan. 14, 2010) — A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research.
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia to be Published in the February 1, 2010 Issue of Clinical Cancer Research
NEW YORK, Jan. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals,...
Adding bortezomib, thalidomide to standard multiple myeloma treatments improved response in older patients
HemOnc today
Posted December 5, 2009
Pairing bortezomib with either melphalan/prednisone or thalidomide/prednisone resulted in favorable response rates among older patients with multiple myeloma, according to data presented at the 51st ASH Annual Meeting.
In addition, lowering the doses of the therapies at induction in favor of maintenance therapy...
